Drug details
Exkivity (mobocertinib capsules)
type of Antineoplastics EGFR Inhibitors
Exkivity (mobocertinib) is a kinase inhibitor used to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This drug may have the following side effects:
- shortness of breath,
- nausea,
- vomiting,
- diarrhea,
- fever,
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- fatigue,
- high blood pressure (hypertension),
- acute kidney injury,
- fluid in the chest,
- fast or irregular heartbeats,
- swelling in the legs, and
- rapid heartbeat
The following drugs are related to Exkivity, either as a replacement or used together:
- Abraxane (albumin-bound paclitaxel for injectable suspension)
- Krazati (adagrasib tablets)
- Gilotrif (afatinib tablets, for oral use)
- Alimta (pemetrexed)
- Alunbrig (brigatinib tablets)
- Rybrevant (amivantamab-vmjw for injection)
- Tecentriq (atezolizumab injection)
- Avastin (bevacizumab)
- Mvasi (bevacizumab-awwb solution for intravenous infusion)
- Zirabev (bevacizumab-bvzr injection)
- Libtayo (cemiplimab-rwlc injection)
- Zykadia (ceritinib hard-gelatin capsules)
- Xalkori (crizotinib)
- Cyramza (ramucirumab solution for intravenous infusion)
- Tafinlar (dabrafenib capsules)
- Imfinzi (durvalumab injection)
- Rozlytrek (entrectinib capsules)
- Tarceva (erlotinib)
- Gavreto (pralsetinib capsules)
- Iressa (gefitinib)
- Gemzar (gemcitabine hcl)
- Keytruda (pembrolizumab for injection)
- Vitrakvi (larotrectinib capsules)
- Lorbrena (lorlatinib tablets)
- Opdivo (nivolumab injection)
- Tagrisso (osimertinib tablets)
- Photofrin (porfimer sodium)
- Retevmo (selpercatinib capsules)
- Sutent (sunitinib malate)